GlaxoSmithKline Consumer Nigeria PLC 1 Industrial Avenue, Ilupeju

RC 8726 PMB 21218 Ikeja, Lagos

Tel: +234 (01) 2711000, (01) 3242900 www.gsk.com/ng

Lagos, March 20, 2023

Board Meeting to be held on Thursday the 23rd day of March, 2023

This is to notify the shareholders of GlaxoSmithKline Consumer Nigeria PLC, Nigerian Exchange Limited, (NGX) and the investing public that a meeting of the Board of Directors of GlaxoSmithKline Consumer Nigeria PLC (the Company) will be held as scheduled on Thursday the 23rd day of March, 2023, to among others, approve the audited financial statements for the year ended December 31, 2022 (2022 AFS).

Consequently, pursuant to Rule 17.18 (a): of the closed period rule of NGX, the Company commenced its closed period on January 1, 2023, which will remain in force until 24 hours after the 2022 AFS have been filed with NGX.

Therefore, no Director, person discharging managerial responsibility, employees with sensitive information and other insiders of the Company and their connected persons shall directly or indirectly deal in the securities of the Company during the closed period.

By Order of the Board

Frederick Ichekwai

Company Secretary

Agbara Factory: Km 32, Igbesa Road, Agbara, Ogun State. Tel: +234 (01) 2918000.Email: Customer_ch_nigeria@gsk.com

Directors: Mr. Edmund Onuzo, Chairman; Mr. Kunle Oyelana, Managing Director; Mr. Samuel Kuye; Mr. Bosco Kirugi (Kenyan), Finance Director;

Mrs. Oludewa Edodo-Thorpe; Ms. Amina Salihu.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Glaxo Smithkline Consumer Nigeria plc published this content on 22 March 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 March 2023 11:02:03 UTC.